Jeremy Haigh, Chief Executive of Proteome Sciences, commented: “While we are satisfied with solid progress during 2016, there is clearly much yet to do if we want to realise the full commercial value of our proteomic technologies. The Company is in a transition phase as we seek to expand our customer base to secure larger and more durable contracts for our services. The recent decision to consolidate our laboratory facilities in Frankfurt was difficult given our UK heritage but we firmly believe it to be in the best interests of the Company and our shareholders. We look forward to healthy progress during 2017, to the imminent arrival of our new Chief Commercial Officer, and to providing further updates through the course of the year.”
After a strong first half, progress continued throughout the rest of the year with results in line with expectations. Buoyed by robust sales of our TMT® reagents and the associated royalties, unaudited revenues during the full year increased by 46%.
Proteome Sciences plc (AIM:PRM) received notification from Vulpes Life Sciences Fund, of which Martin Diggle, a non-executive director of the Company, is a director and partner, that today, it purchased 105,590 ordinary shares of 1 pence each at 5.5 pence per Ordinary Share.
Proteome Sciences plc (AIM:PRM) received notification from Vulpes Life Science Fund (“Vulpes”), of which Martin Diggle, a non-executive director of the Company, is a director and partner, that on 28, 29 and 30 December 2016, it purchased 265,000, 250,000 and 350,000 ordinary shares of 1 pence each (“Ordinary Shares”) respectively, at an average price of 5.74 pence per Ordinary Share (the “Transaction”).
Proteome Sciences is pleased to announce the launch of its newly designed corporate website, as anticipated in the Company’s interim results statement of 14 September 2016.
Proteome Sciences plc (AIM:PRM) is pleased to announce that at its General Meeting held earlier today, all resolutions were duly passed.
Proteome Sciences partners with the BioCapture Network in this interdisciplinary project we will design high affinity responsive molecular capture materials targeting tumor specific markers. Molecularly imprinted polymers or “plastic antibodies” and other smart materials will be developed and used to detect and sense previously inaccessible tumor markers or to discover novel disease biomarkers.
Notice of a General Meeting of Proteome Sciences Plc, to be held at the offices of finnCap, 60 New Broad Street, London, EC2M 1JJ at 10 a.m. on 29 November 2016.
genomeweb.com-"The company hopes that looking at multiple species of the phosphorylated tau protein could allow for earlier and more accurate diagnosis of the disease."